Results 201 to 210 of about 56,913 (295)

CYP3A4 wt Allele [PDF]

, 2020
openaire   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3716-3732, November 2026.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Interactions between cytochrome P450 enzymes and traditional Chinese herbs: A comprehensive review. [PDF]

J Chin Med Assoc
Hsieh YH, Huang ST.
europepmc   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3770-3777, November 2026.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Food Effects, Pharmacokinetic Drug-Drug Interactions, and Clinical Optimization of Oral Anticancer Agents. [PDF]

Pharmaceutics
Assiri AA.
europepmc   +1 more source

Sedative Potential of L (+)‐Tartaric Acid: Behavioral Evidence With In Silico Insights Into Possible GABAergic Interaction

Brain and Behavior, Volume 16, Issue 11, November 2026.
ABSTRACT Purpose Insomnia is a prevalent neurological disorder often caused by stress, anxiety, and imbalances in the GABAergic system. Although benzodiazepines like diazepam (DZP) are commonly prescribed, their long‐term use is associated with adverse effects, including dependence and impaired coordination.
Sumaya Akter Bithi, Anike Chakrabarty, Khadija Akter, Chinmoy Kumar Saha, Mohammad Y. Alshahrani, Md. Arif Hossain, Emon Mia, Noshin Tasnim Yana, Afiya Ajmee, Proma Mandal, Md. Sakib Al Hasan, Muhammad Torequl Islam   +11 more
wiley   +1 more source

α‑Lipoic Acid and Deferoxamine Restore Redox-Metallomic Homeostasis in Dapsone Toxicity: Integrated Biochemical, Histological, and Molecular Modeling Evidence. [PDF]

ACS Omega
Mesquita da Silva RK, Monteiro ACDS, Freitas SKF, Santana APH, Davis K, Lima WGN, Seabra PSDS, Sodré DF, do Amarante CB, Carneiro ADS, de Sousa AQD, Dos Santos SM, Gomes ARQ, Gomes BAQ, Ferreira RG, Monteiro MC.   +15 more
europepmc   +1 more source

Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High‐Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely ...
Nadia Linxi Feng, John Doering, Tzu‐Fei Wang, Ranjeeta Mallick, Grégoire Le Gal, Joseph Shaw, Danny Hill, Sudeep Shivakumar, Vicky Tagalakis, Phil Wells, Marc Carrier   +10 more
wiley   +1 more source

Metabolic Activation-Dependent Anti-Liver Cancer Activity and Organ-Specific Toxicity of Retrorsine From Fanhuncao (Jacobaea cannabifolia and J. litvinovii). [PDF]

Arch Pharm (Weinheim)
He Z, Tan Z, Zhang L, Yin Y, Yerjiang Y, Bi B, Bao J.   +6 more
europepmc   +1 more source

Pharmacogenomics in Cancer Treatment: Challenges and Opportunities in African Settings

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Cancer incidence in Africa is projected to reach 2.1 million new cases annually by 2040. Current treatment guidelines remain largely based on pharmacogenomic data predominantly from European and Asian genetic profiles, potentially compromising safety and efficacy in African patients.
Ntombikhona Fortunate Maphumulo, George Rebello, Veron Ramsuran   +2 more
wiley   +1 more source